Key clinical highlights and key takeaways from ECCMID 2022 are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Chaidari, Greece; Chair, European Sepsis Alliance). He discusses the burden of drug resistance in antimicrobials, and the main drugs in the market and emerging treatments. He also discusses his thoughts on the latest advances in his research group.
Questions:
- What are the key clinical highlights from ECCMID 2022? (0:16)
- What are the hot topics and latest research you are looking forward to exploring in 2022? (3:07)
Disclosures: Evangelos Giamarellos-Bourboulis receives honoraria (paid to the University of Athens) from Abbott CH, Brahms, ThermoFisher GmbH Germany, GSK, and Sobi; he is also a consultant for Abbott CH, Fab’nTech, InflaRx GmbH, UCB, Sobi, and Xbiotech Inc; he also receives research grants (paid to the University of Athens) from AbbVie USA, InflaRx GmbH, Novartis, and UCB; he also receives research grants (paid to the Hellenic Institute for the Study of Sepsis) from Abbott CH, bioMérieux France, Johnson & Johnson, MSD, Sobi, and ThermoFisher Brahms GmbH. Evangelos Giamarellos-Bourboulis also received EU research funding from Horizon 2020 ITN European Sepsis Academy (granted to the University of Athens), Horizon 2020 ImmunoSep and RISCin COVID (granted to the Hellenic Institute for the Study of Sepsis), and Horizon 2020 EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
